About MannKind (NASDAQ:MNKD)
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Debt
Debt-to-Equity Ratio-0.48%
Current Ratio0.65%
Quick Ratio0.62%
Price-To-Earnings
Trailing P/E Ratio-1.54
Forward P/E Ratio-2.11
P/E GrowthN/A
Sales & Book Value
Annual Sales$11.74 million
Price / Sales20.29
Cash FlowN/A
Price / CashN/A
Book Value($1.81) per share
Price / Book-0.99
Profitability
EPS (Most Recent Fiscal Year)($1.16)
Net Income$-117,330,000.00
Net Margins-999.00%
Return on EquityN/A
Return on Assets-159.22%
Miscellaneous
Employees250
Outstanding Shares133,050,000
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.29) by $0.01. The biopharmaceutical company had revenue of $4.53 million for the quarter, compared to the consensus estimate of $3.22 million. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
4 equities research analysts have issued 12-month price objectives for MannKind's shares. Their predictions range from $1.00 to $2.77. On average, they anticipate MannKind's stock price to reach $1.59 in the next year. View Analyst Ratings for MannKind.
What are Wall Street analysts saying about MannKind stock?
Here are some recent quotes from research analysts about MannKind stock:
- 1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (4/6/2018)
- 2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)
Are investors shorting MannKind?
MannKind saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 35,944,357 shares, an increase of 1.2% from the March 15th total of 35,523,152 shares. Based on an average trading volume of 1,481,058 shares, the short-interest ratio is currently 24.3 days. Currently, 34.6% of the company's shares are short sold.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Depomed (DEPO), Synergy Pharmaceuticals (SGYP), Syros Pharmaceuticals (SYRS), Paratek Pharmaceuticals (PRTK), Cytokinetics (CYTK), Cara Therapeutics (CARA), Kala Pharmaceuticals (KALA), Corium International (CORI), Albireo Pharma (ALBO), Mersana Therapeutics (MRSN), Durect (DRRX), Strongbridge Biopharma (SBBP), Corbus Pharmaceuticals (CRBP), GTX (GTXI), Clearside Biomedical (CLSD), Dermira (DERM), Kadmon (KDMN) and Merus (MRUS).
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 41)
- Dr. David B. Thomson, Gen. Counsel & Corp. Sec. (Age 51)
- Mr. Steven B. Binder, Chief Financial Officer (Age 55)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 54)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 57)
Has MannKind been receiving favorable news coverage?
Media coverage about MNKD stock has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. MannKind earned a news sentiment score of 0.03 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are MannKind's major shareholders?
MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional investors include SABBY MANAGEMENT, LLC (5.57%). Company insiders that own MannKind stock include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Raymond W Urbanski, Rosabel Realica Alinaya and Stuart A Tross. View Institutional Ownership Trends for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $1.79.
How big of a company is MannKind?
MannKind has a market capitalization of $223.53 million and generates $11.74 million in revenue each year. The biopharmaceutical company earns $-117,330,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. MannKind employs 250 workers across the globe.
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 301, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
MannKind (NASDAQ:MNKD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for MannKind in the last 12 months. Their average twelve-month price target is $1.59, suggesting that the stock has a possible downside of 11.17%. The high price target for MNKD is $2.77 and the low price target for MNKD is $1.00. There are currently 3 sell ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.50 | 1.50 | 1.75 | 2.00 |
| Ratings Breakdown: | 3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 3 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.59 | $1.59 | $0.9150 | $0.9150 |
| Price Target Upside: | 11.17% downside | 49.68% downside | 71.85% downside | 82.83% downside |
MannKind (NASDAQ:MNKD) Consensus Price Target History
MannKind (NASDAQ:MNKD) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
MannKind (NASDAQ:MNKD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
MannKind (NASDAQ MNKD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.97%
Institutional Ownership Percentage: 17.73%
MannKind (NASDAQ MNKD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/21/2017 | Stuart A Tross | VP | Buy | 39,840 | $2.52 | $100,396.80 | 59,840 |  |
| 12/20/2017 | Michael Castagna | CEO | Buy | 8,000 | $2.29 | $18,320.00 | 35,532 | |
| 10/13/2017 | Kent Kresa | Director | Buy | 166,600 | $6.00 | $999,600.00 | | |
| 8/10/2017 | Raymond W Urbanski | CMO | Sell | 296 | $1.15 | $340.40 | 2,924 | |
| 6/30/2017 | Rosabel Realica Alinaya | SVP | Buy | 2,000 | $1.23 | $2,460.00 | 30,091 | |
| 1/3/2017 | Matthew J Pfeffer | CEO | Buy | 4,540 | $0.54 | $2,451.60 | 403,085 | |
| 1/3/2017 | Rosabel Realica Alinaya | SVP | Buy | 9,043 | $0.54 | $4,883.22 | 140,456 | |
| 8/26/2016 | Michael Castagna | Insider | Buy | 17,500 | $0.78 | $13,650.00 | 212,500 | |
| 8/24/2016 | Michael Castagna | Insider | Buy | 15,000 | $0.87 | $13,050.00 | 195,000 | |
| 8/23/2016 | Michael Castagna | Insider | Buy | 25,000 | $0.94 | $23,500.00 | 180,000 | |
| 8/15/2016 | Matthew J Pfeffer | CEO | Buy | 25,000 | $0.99 | $24,750.00 | 397,996 | |
| 8/12/2016 | Michael Castagna | Insider | Buy | 25,000 | $1.00 | $25,000.00 | 75,000 | |
| 5/17/2016 | Michael Castagna | Insider | Buy | 50,000 | $0.93 | $46,500.00 | 50,000 | |
| 4/24/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $4.83 | $354,811.80 | | |
| 3/27/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $5.21 | $382,726.60 | | |
| 2/10/2015 | Hakan Edstrom | CEO | Sell | 73,460 | $7.75 | $569,315.00 | | |
| 2/5/2015 | David Thomson | VP | Sell | 80,000 | $7.00 | $560,000.00 | | |
| 1/5/2015 | Diane Palumbo | VP | Sell | 188,999 | $5.95 | $1,124,544.05 | | |
| 11/24/2014 | David Thomson | VP | Sell | 118,114 | $6.14 | $725,219.96 | | |
| 10/3/2014 | Juergen Martens | VP | Sell | 63,800 | $5.48 | $349,624.00 | | |
| 8/27/2014 | Juergen Martens | VP | Sell | 417 | $7.60 | $3,169.20 | | |
| 8/7/2014 | David Thomson | VP | Sell | 30,000 | $8.16 | $244,800.00 | | |
| 7/21/2014 | Juergen Martens | VP | Sell | 26,458 | $9.65 | $255,319.70 | | |
| 7/15/2014 | Diane Palumbo | VP | Sell | 17,901 | $10.01 | $179,189.01 | | |
| 7/1/2014 | Matthew J Pfeffer | CFO | Sell | 20,000 | $10.44 | $208,800.00 | | |
| 6/30/2014 | Hakan Edstrom | COO | Buy | 1,692 | $4.42 | $7,478.64 | | |
| 6/27/2014 | Juergen Martens | VP | Sell | 25,417 | $10.53 | $267,641.01 | | |
| 6/26/2014 | David Thomson | VP | Sell | 30,000 | $10.51 | $315,300.00 | | |
| 6/20/2014 | Juergen Martens | VP | Sell | 1,458 | $10.34 | $15,075.72 | | |
| 6/16/2014 | Diane Palumbo | VP | Sell | 17,902 | $10.59 | $189,582.18 | | |
| 6/5/2014 | Juergen Martens | VP | Sell | 120,000 | $11.00 | $1,320,000.00 | | |
| 6/4/2014 | David Thomson | VP | Sell | 133,000 | $9.95 | $1,323,350.00 | | |
| 6/3/2014 | Diane Palumbo | VP | Sell | 52,957 | $9.50 | $503,091.50 | | |
| 5/23/2014 | Juergen Martens | VP | Sell | 25,000 | $7.65 | $191,250.00 | | |
| 5/19/2014 | Juergen Martens | VP | Sell | 76,899 | $7.50 | $576,742.50 | 139,024 | |
| 5/15/2014 | Diane Palumbo | VP | Sell | 18,176 | $7.06 | $128,322.56 | 158,858 | |
| 1/24/2014 | Juergen Martens | VP | Sell | 50,000 | $5.56 | $278,000.00 | 139,450 | |
| 12/31/2013 | Hakan Edstrom | COO | Buy | 1,589 | $4.53 | $7,198.17 | 729,685 | |
| 12/20/2013 | Juergen Martens | VP | Sell | 32,054 | $5.00 | $160,270.00 | 139,450 | |
| 12/11/2013 | David Thomson | VP | Sell | 150,000 | $5.00 | $750,000.00 | 83,752 | |
| 11/29/2013 | Juergen Martens | VP | Sell | 48,057 | $5.01 | $240,765.57 | 171,504 | |
| 11/15/2013 | Diane Palumbo | VP | Sell | 25,000 | $5.02 | $125,500.00 | 112,756 | |
| 8/28/2013 | David Thomson | VP | Sell | 19,204 | $5.78 | $110,999.12 | 40,082 | |
| 8/26/2013 | Juergen Martens | VP | Sell | 20,000 | $5.52 | $110,400.00 | 136,016 | |
| 8/1/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $8.00 | $80,000.00 | | |
| 7/2/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $7.00 | $70,000.00 | | |
| 6/30/2013 | Diane Palumbo | VP | Buy | 1,610 | $1.96 | $3,155.60 | | |
| 6/30/2013 | Matthew J Pfeffer | CFO | Buy | 7,448 | $1.96 | $14,598.08 | | |
| 6/3/2013 | Diane Palumbo | VP | Sell | 66,849 | $7.50 | $501,367.50 | | |
| 5/16/2013 | Diane Palumbo | VP | Sell | 26,829 | $5.25 | $140,852.25 | | |
| 5/15/2013 | Matthew J Pfeffer | CFO | Sell | 10,000 | $5.00 | $50,000.00 | | |
| 12/31/2012 | Matthew J Pfeffer | CFO | Buy | 1,056 | $1.95 | $2,059.20 | | |
| 12/21/2012 | Alfred E Mann | Major Shareholder | Buy | 40,000,000 | $2.59 | $103,600,000.00 | | |
(Data available from 1/1/2013 forward)
MannKind (NASDAQ MNKD) News Headlines
| Source: |
|
MannKind (NASDAQ:MNKD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
MannKind (NASDAQ:MNKD) Income Statement, Balance Sheet and Cash Flow Statement
MannKind (NASDAQ MNKD) Stock Chart for Thursday, April, 19, 2018
Loading chart…
